Clinical Trial Update: HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical study is evaluating 89Zr-trastuzumab PET/CT imaging as a predictive biomarker to help sequence antibody-drug conjugates in patients with adva…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• 89Zr-trastuzumab (zirconium-89-labeled trastuzumab)
• HERCEPTIN (trastuzumab)

Snippet

Sponsor: Jules Bordet Institute | Conditions: HER2-positive Metastatic Breast Cancer, HER2-positive Advanced Breast Cancer | Phase 2 | Status: RECRUITING